Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by gebremeskelon Jan 30, 2024 3:11pm
183 Views
Post# 35853312

RE:RE:RE:RE:RE:RE:New Press Release - Spectral Medical Provides January Tigris Trial Update

RE:RE:RE:RE:RE:RE:New Press Release - Spectral Medical Provides January Tigris Trial UpdateIf you have to explain a joke it spoils it! Nonetheless....

20 days ago, in the January 10 news release Dr. Kellum stated:

"Overall, we are rapidly advancing our Tigris trial and remain highly encouraged by the outlook, given the fact preliminary mortality data continues to exceed our expectations.”

This news release also revealed that the 82nd patient had been enrolled.

If BlueJays9293 is correct and  it takes 28 days from the time of enrolment to get mortality data there could only be short term mortality data for one additional patient since the Jan.10 news release.

How could the results from a single patient possibly effect the encouraging statement that preliminary mortality data from the first 81 patients continues to exceed expectations?

Sorry for belaboring the point, but to me the omission of the statement was clearly an oversight, and focussing on that rather than the good news that we are only 5 patients away from 90 struck me as funny - a quintessentially glass-half-empty response. 

palinc2000 wrote:

I dont know what is funny in my pointing out a very significant omission in today s PR especially since ALL  trial up dates since at least November 2022 either mentioned encouraging results or results exceeding expectations so far!!!
 

I dont have any problens with the delays encountered so far ....ALL I am interested in are trial results and  I get very excited if they  exceed expectations!!
The omission is voluntary imo but I dont know why it was left out....
You seem to know why .... just tell us then
 

gebremeskel wrote: Your takeaway from today's news release.

palinc2000 wrote:

What doyou find funny?

gebremeskel wrote: Very funny! Just 5 patients to go.

palinc2000 wrote: No more mention of results exceeding expectations...???




 




 



<< Previous
Bullboard Posts
Next >>